Form 8-K

8-K — Vivos Therapeutics, Inc.

Accession: 0001493152-26-016865

Filed: 2026-04-15

Period: 2026-04-15

CIK: 0001716166

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001716166

2026-04-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): April 15, 2026

Vivos

Therapeutics, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39796

81-3224056

(State

or other jurisdiction

(Commission

(I.R.S.

Employer

incorporation)

File

Number)

Identification

No.)

7921

Southpark Plaza, Suite 210

Littleton,

Colorado 80120

(Address

of principal executive offices) (Zip Code)

(866)

908-4867

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

VVOS

The

NASDAQ Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02. Results of Operations and Financial Condition.

April 15, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the

fiscal year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K

and is incorporated herein by reference.

The

information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section

18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that

Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended,

or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release of the Company, dated April 15, 2026, announcing its financial results for the fiscal year ended December 31, 2025.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

VIVOS

THERAPEUTICS, INC.

Dated:

April 15, 2026

By:

/s/

Bradford Amman

Name:

Bradford

Amman

Title:

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Vivos

Therapeutics Reports Full Year 2025 Financial Results

Full

Year 2025 revenue increased 16%

Integration

of The Sleep Center of Nevada and shift business model support path to improved revenues, margins and cash flow

Management

to Host Conference Call today at 5:00 pm ET

LITTLETON,

Colo., April 15, 2026

–

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device

and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions,

including obstructive sleep apnea (“OSA”), today reported financial results and operating highlights for the full year ended

December 31, 2025.

Full

Year 2025 Financial and Operating Summary

●

Revenue

was $17.5 million for the year ended December 31, 2025, compared to $15.0 million for the full year ended December 31, 2024, a year

over year increase of 16%. The increase in revenue was mainly due to an increase in sleep testing services and an increase in revenue

from the treatment of OSA patients at two Nevada locations of The Sleep Center of Nevada (SCN), both offset by the expected

wind down of Vivos Integrated Practice (VIP) enrollment revenue. Vivos acquired the operating assets of SCN in June 2025;

●

Gross

profit was $10.5 million for the year ended December 31, 2025 compared with $9.0 million for the full year ended December 31, 2024,

an increase of 17%;

●

Gross

margin remained at 60% for the years ended December 31, 2025 and December 31, 2024;

●

Operating

expenses for the year ended December 31, 2025 was $30.4 million, compared to $20.2 million for the year ended December 31, 2024,

the increase relating in part to costs associated with integrating and managing SCN operations and related OSA treatment centers;

●

Vivos’

acquisition of the operating assets of SCN and investments in that business resulted in an operating loss of $19.9 million for the

full year ended December 31, 2025, versus a loss of $11.2 million for the year ended December 31, 2024;

●

Cash

and cash equivalents were $2.0 million as of December 31, 2025, and Vivos’ cash position was augmented subsequent to year end

by two financing transactions for aggregate gross proceeds of $6.8 million.

Vivos’

2025 results of operations reflect its continued pivot in business strategy and steady decrease in its prior focus on enrolling and training

VIP dentists to sell Vivos’ proprietary OSA treatments. Vivos’ new business strategy is focused on contractual alliances

with and outright acquisitions of sleep specialty medical providers, sleep testing centers and other similar entities.

Kirk

Huntsman, Vivos’ Chairman and Chief Executive Officer, stated “2025 was a pivotal year for Vivos. We grew full-year revenue

by 16%, maintained gross margin despite significant investment, driven primarily by the continued ramp of our sleep testing services

and the integration of The Sleep Center of Nevada. While our operating loss reflects the upfront investments in this new model, we believe

these actions, together with recent significant cost-savings initiatives and strengthened capital structure, position Vivos to drive

higher top-line growth, better contribution margins, and a clear path toward our goal of cash flow positive operations by end of this

year.”

Vivos

encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time (details below), where

management will discuss further details on topics including Vivos’ strategic initiatives and the anticipated effect on Vivos’

near-term revenue growth and cash burn.

addition, further information on Vivos’ financial results is included on the attached condensed consolidated balance sheets and

statements of operations, and additional explanations of Vivos’ financial performance are provided in the Vivos’ Annual Report

on Form 10-K for the twelve months ended December 31, 2025, which was filed today with the Securities and Exchange Commission (“SEC”).

The full 10-K report will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.

Conference

Call

access Vivos’ investor conference call, please dial (800) 717-1738 or (646) 307-1865 for international callers. A replay will be

available shortly after the call and can be accessed by dialing (844) 512-2921 or (412) 317-6671 for international callers. The passcode

for the replay is 1153783. The replay will be available until April 29, 2025

live webcast of the conference call is available on Vivos’ website at https://vivos.com/investor-relations. An online archive

of the webcast will be available on the Company’s website for 30 days following the call.

About

Vivos Therapeutics, Inc.

Vivos

Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing

innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities

such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration

(FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’

groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating

severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.

OSA

affects over 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is

not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides

in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments

like CPAP are often mechanistic and fail to address the root causes of OSA.

Founded

in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions

of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs

of OSA patients more thoroughly.

Vivos

calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective

solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For

more information, visit www.vivos.com.

Cautionary

Note Regarding Forward-Looking Statements

This

press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith

contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E

of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”,

“expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”,

“hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to

identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions

and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control.

Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos’ future

revenues and results of operations and the anticipated benefits of the Company’s new marketing and distribution model described

herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause

actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales

and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results

from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector;

(iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq

listing due to, among other things, a deficiency in its stockholders’ equity; (v) market and other conditions, and (vi) other risk

factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge on the SEC’s website

at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any

updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect

thereto or any change in events, conditions, or circumstances on which any statement is based.

Vivos

Investor Relations and Media Contact:

Bradford

Amman

Chief

Financial Officer and Investor Relations Contact

investors@vivoslife.com

-Tables

Follow-

VIVOS

THERAPEUTICS, INC.

Consolidated

Balance Sheets

December

31, 2025 and 2024

(In

Thousands, Except Per Share Amounts)

2025

2024

Current assets

Cash and cash equivalents

$ 2,029

$ 6,260

Accounts receivable, net of allowance of $882 and $390, respectively

1,581

430

Prepaid expenses and other current assets

774

783

Total current assets

4,384

7,473

Long-term assets

Goodwill

8,572

2,843

Property and equipment, net

3,757

3,311

Operating lease right-of-use asset

4,166

1,032

Intangible assets, net

4,045

409

Deposits and other

228

216

Total assets

$ 25,152

$ 15,284

LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)

Current liabilities

Accounts payable

$ 1,679

$ 1,098

Accrued expenses

5,988

2,234

Current portion of contract liabilities

479

896

Current portion of operating lease liability

672

477

Current portion of financing lease liability

Current portion of debt

8,353

Other current liabilities

850

273

Total current liabilities

18,076

4,978

Long-term liabilities

Contract liabilities, net of current portion

Employee retention credit liability

2,904

1,220

Operating lease liability, net of current portion

3,840

1,035

Financing lease liability, net of current portion

113

Debt, net of current portion

469

Other liabilities

1,300

Total liabilities

26,702

7,330

Commitments and contingencies

Stockholders’ equity/(deficit)

Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding

Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 9,286,609 shares as of December 31, 2025 and 5,889,520 shares as December 31, 2024

Additional paid-in capital

123,866

112,141

Accumulated deficit

(125,357 )

(104,187 )

Total stockholders’ equity/(deficit)

(1,490 )

7,954

Non-controlling interest

Total equity/(deficit)

(1,550 )

7,954

Total liabilities and equity/(deficit)

$ 25,152

$ 15,284

VIVOS

THERAPEUTICS, INC.

Consolidated

Statements of Operations

Years

Ended December 31, 2025 and 2024

(In

Thousands, Except Per Share Amounts)

2025

2024

Revenue

Product revenue

$ 6,487

$ 7,874

Service revenue

10,956

7,157

Total revenue

17,443

15,031

Cost of sales (exclusive of depreciation and amortization shown separately below)

6,901

6,012

Gross profit

10,542

9,019

Operating expenses

General and administrative

27,727

17,878

Sales and marketing

1,400

1,731

Depreciation and amortization

1,309

581

Total operating expenses

30,436

20,190

Operating loss

(19,894 )

(11,171 )

Non-operating income (expense)

Other expense

(1,481 )

(110 )

Other income

145

Loss before income taxes

(21,230 )

(11,136 )

Net loss

$ (21,230 )

$ (11,136 )

Net loss attributable to non-controlling interest

(60 )

Net loss attributable to stockholders

$ (21,170 )

$ (11,136 )

Net loss per share (basic and diluted)

$ (2.07 )

$ (2.22 )

Weighted average number of shares of Common Stock outstanding (basic and diluted)

10,273,881

5,019,886

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Apr. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 15, 2026

Entity File Number

001-39796

Entity Registrant Name

Vivos

Therapeutics, Inc.

Entity Central Index Key

0001716166

Entity Tax Identification Number

81-3224056

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7921

Southpark Plaza

Entity Address, Address Line Two

Suite 210

Entity Address, City or Town

Littleton

Entity Address, State or Province

Entity Address, Postal Zip Code

80120

City Area Code

(866)

Local Phone Number

908-4867

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

VVOS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration